News Posts List
Granulocytosis and Thrombocytosis in Renal Cell Carcinoma
03/04/2010
A 79-year-old female with renal cell carcinoma (RCC) presents with low back pain, low-grade fever, and weight loss. Laboratory tests, computed tomography, and immunohistochemical analysis are described; images provided.
Translocation Renal Cell Carcinoma Occurring During Pregnancy
03/04/2010
A 26-year-old female at 14 weeks gestation presents with a complex cystic renal mass. Analysis of histology, immunohistochemistry, cytogenetics, and fluorescence in situ hybridisation are described; images provided.
Kidney cancer treatment sales to increase to $6.5 billion by 2015
03/04/2010
The RCC market has recently attracted significant investments in research and development from big pharma, specialty pharma, and biotechnology companies.
Ubiquitin-dependent degradation in human renal cell carcinoma
03/03/2010
Reduction of transforming growth factor- type II receptor is caused by the enhanced ubiquitin-dependent degradation in human renal cell carcinoma.
Composite renal cell carcinoma
03/03/2010
Composite renal cell carcinoma with clear cell renal cell carcinomatous and carcinoid tumoral elements: A first case report - Abstract.
Percutaneous biopsy of renal cell carcinoma
03/03/2010
To assess the accuracy of renal biopsy for predicting the final nuclear grade and histologic subtype. Small renal masses can be safely observed in select patients who are poor surgical candidates. Renal biopsy may help identify patients who are candidates for observation.
Scientists Turn Off Resistance to Sunitinib
03/03/2010
Van Andel Research Institute (VARI) researchers have found a way to reverse resistance to sunitinib, a treatment that is currently the first line of defense against clear cell renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Most patients who show a positive response to sunitinib develop a resistance to the drug after one year of treatment.
Renal Cell Carcimona Drug Discoveries - What the Future Holds
03/02/2010
With the advent of the new targeted therapies there has been a complete shift in paradigm. Treatment options for patients with advanced disease have improved dramatically; until recently there was limited choice and therapies were poorly tolerated, with relatively low response rates. Patients now face multiple options with improved safety and efficacy, and there are plenty of further therapies in the pipeline. The overall prognosis has changed for these patients and survival is now much longer.
FactCheck.org: Republican & Democrat Health Reform Plans
03/02/2010
Contrary to claims made by some Democratic detractors, detailed GOP proposals, and a bipartisan bill with several GOP cosponsors, do exist.
News Feed